ZEB2 and colorectal carcinoma: The benefit of administering adjuvant chemotherapy in stage III CRC is well recognized.30 Selecting node-negative patients (stages I to II disease) who benefit from adjuvant chemotherapy using conventional assessment remains suboptimal, however.31 Consequently, we next investigated whether ZEB2 expression in node-negative patients could identify patients at higher risk for recurrence.